Perrigo Co. PLC won't have strong quarterly results to help management convince investors about their turnaround strategy that swings on a change the firm says started during its latest quarter, moving from health care to self-care.
Perrigo's Q1 Results Offer Scant Support To Promote Its 'Self-Care' Turnaround
President and CEO Murray Kessler attempts to temper expectations before investor day on May 9 saying Perrigo's turnaround under strategy implemented after he joined firm in November is in its early days. Private label leader, however, will report another step in its move to return to being consumer product-focused: agreement to sell its animal health business to PetIQ for $185m cash.
More from Business
• By
The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.
• By
Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.
• By
While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.
• By
The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.
More from Health
• By
The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.
• By
HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.
• By
Energy and Commerce Health Subcommittee members, including several health care professionals, make clear their concerns about the US sunscreen market during hearing on reauthorizing FDA’s OMUFA program.